Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N
The Third Department of Internal Medicine, Nagoya University School of Medicine, Showa-ku, Japan.
Am J Kidney Dis. 1997 Aug;30(2):275-8. doi: 10.1016/s0272-6386(97)90064-0.
Sclerosing peritonitis (SCP) is a rare complication of peritoneal dialysis. Most of the patients with this serious complication have been treated in a symptomatic and conservative manner. Other patients have undergone risky surgical interventions. Recently it was reported that immunosuppressive therapy after renal transplantation was effective for this complication. A 56-year-old man developed sclerosing peritonitis 5 months after switching from peritoneal dialysis to hemodialysis because of ultrafiltration failure. The patient had ongoing inflammatory signs and symptoms, and corticosteroid therapy was commenced. His condition was dramatically improved within 1 week, and he is now well on an outpatient basis with the maintenance dosage of corticosteroid. This is the first report of a patient with peritoneal dialysis-related SCP who responded favorably to corticosteroid therapy alone.
硬化性腹膜炎(SCP)是腹膜透析的一种罕见并发症。大多数患有这种严重并发症的患者都接受了对症和保守治疗。其他患者则接受了风险较大的手术干预。最近有报道称,肾移植后的免疫抑制治疗对这种并发症有效。一名56岁男性因超滤失败从腹膜透析转为血液透析5个月后发生了硬化性腹膜炎。该患者持续存在炎症体征和症状,于是开始使用皮质类固醇治疗。他的病情在1周内显著改善,现在作为门诊患者情况良好,维持使用皮质类固醇剂量。这是首例仅对皮质类固醇治疗有良好反应的腹膜透析相关SCP患者的报告。